EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries. (2023)

First Author: Elshatlawy M
Attributed to:  Understanding and targeting oncogenic biomolecular condensates of ALK kinase funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/1878-0261.13446

PubMed Identifier: 37149843

Publication URI: http://europepmc.org/abstract/MED/37149843

Type: Journal Article/Review

Volume: 17

Parent Publication: Molecular oncology

Issue: 6

ISSN: 1574-7891